New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS

New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS